Here the authors report the design of a peptide-antibody combo-supramolecular in situ assembled CD47 and CD24 bi-target inhibitor that enhances the phagocytic ability of macrophages and improves response to anti-PD-1 in preclinical cancer models. Here, CD47 is linked to cancer.